BMAC (Bone Marrow Aspirate Concentrate) injection is an advanced regenerative therapy offered at the London Cartilage Clinic. This cutting-edge treatment utilizes the healing properties of the patient's own bone marrow cells to treat various knee conditions, including osteoarthritis, sports injuries, and cartilage damage. BMAC injections are minimally invasive and provide a promising alternative to more extensive knee surgeries.
BMAC therapy uses your own bone marrow aspirate, concentrated to increase the cellular and growth-factor components delivered to the affected area.
This approach aims to reduce inflammation, improve function, and support tissue repair while avoiding more invasive surgery in selected cases.
BMAC is often selected for patients seeking a biologic, minimally invasive option for degenerative or sports-related knee conditions.
At London Cartilage Clinic, BMAC protocols are specialist-led and individualised to your pathology, imaging findings, and recovery goals.
You may have more options than you think
At London Cartilage Clinic we follow a structured clinical framework across four areas of treatment. Before recommending a single procedure, we assess which combination of approaches gives you the best outcome.
Protect what you have. Slow degeneration and manage symptoms.
Fix specific damage. Torn tissue, unstable joints, structural problems.
Rebuild lost tissue. Biological treatments that stimulate new growth.
When other options are exhausted. Joint replacement as a last resort.
This treatment can be applied across multiple joints. Select yours to see the full range of options we offer, organised by clinical approach.
Explore All Treatment Options
BMAC injections are effective in treating a range of knee conditions, including osteoarthritis, sports-related injuries, and cartilage degeneration.
Patients typically experience minimal discomfort during the BMAC injection procedure. Local anesthesia is used to ensure patient comfort.
Results can vary, but many patients report improvement in pain and mobility within a few weeks of the treatment. The full benefits of the injection may continue to develop over several months.
Still have more specific concerns?
Free Discovery CallLondon Cartilage Clinic
Clinical updates, cartilage treatment guidance, and recovery-focused articles from our specialist team.
ChondroFiller injection has produced no serious adverse effects across 19,000+ clinical cases since 2013; the complaint rate stands at 0.06%, among the lowest in cartilage repair. Post-injection swelling, pain, and stiffness resolve within 48–72 hours, but follow-up data beyond three years remain sparse.
In roughly half of ACL ruptures, articular cartilage sustains damage at the moment of rupture. The joint's inflammatory cascade thereafter actively degrades cartilage matrix, which cannot self-repair; this initiates osteoarthritis typically a decade earlier than in uninjured peers.
Functional recovery from ChondroFiller outpaces structural repair: patients achieve a clinically meaningful 30-point IKDC improvement within twelve months, but cartilage maturation on MRI continues beyond that functional plateau.
